GLP-1 Explained: Natural vs Injectable Approaches to Appetite & Weight Control

Unless you've been living under a rock, you’ve heard everyone talking about those weight-loss injections—semaglutide (sold as Wegovy and Ozempic) and tirzepatide (known as Zepbound and Mounjaro). But have you ever wondered what makes them tick? Let's break it all down in a way that actually makes sense!

Meet GLP-1: Your Body's "Feel Full" Signal

GLP-1 is the secret ingredient that connects all three options—semaglutide, tirzepatide, and Amarasate (Calocurb): a hormone with the mouthful of a name, glucagon-like peptide-1, or GLP-1 for short (because seriously, who has time to say all that?). This clever little hormone does two main jobs: keeping your blood sugar in check and letting your brain know when you've eaten enough.

Every time you sit down for a meal, special cells lining your intestines kick into gear and pump out GLP-1. You'll see a quick spike right after eating, followed by another bump a bit later. Once released, this hormone makes its rounds through your body, visiting important spots like your pancreas and brain to work its magic. But here's the catch: your body has an enzyme called DPP-4 that acts like a GLP-1 demolition crew, breaking down most of it very quickly, so its effects are quite short-lived.

How GLP-1 Finds Its Target

Think of your body as being covered in thousands of tiny docking stations called receptors, each designed for specific molecules. GLP-1 has its own special set of receptors scattered throughout your body—imagine them as locks that only GLP-1 keys can open. You'll find these locks in your pancreas, digestive tract, and brain— indeed, throughout your body. When GLP-1 slides into one of these receptors and turns the key, different things happen depending on which part of your body that receptor calls home.

What Happens When GLP-1 Gets to Work

GLP-1 is quite the multitasker, though scientists are still figuring out everything it does. In your digestive system, it puts the brakes on how quickly your stomach empties, tells your pancreas to make more insulin (which helps manage blood sugar), and encourages your liver to soak up glucose. Up in your brain, GLP-1 creates that satisfying "I'm full" feeling (the fancy term is 'increased satiety'). Between the slower stomach emptying and feeling satisfied, your body is basically getting a clear message: “Okay, you can put down the fork now!” That's why you can think of GLP-1 as your body's way of saying, 'you've had enough to eat.'

GLP-1 also influences your cardiovascular system, nudging your heart rate and blood pressure upward. It might help your muscles process glucose more efficiently and play a role in how your body stores fat. Scientists are also buzzing with excitement about other potential brain-related effects, including possible impacts on addictive behaviors.

The Amarasate (Calocurb) Approach: Working with Your Body

What it does

Amarasate comes from an unexpected source—bitter hops flowers cultivated in New Zealand. It’s been developed as a nutraceutical supplement in New Zealand, with over 15 years of research, largely backed by the New Zealand government. Amarasate takes advantage of something pretty fascinating: those bitter taste receptors on your tongue? They're not just on your tongue! (Mind-blowing, right?) They're actually scattered all through your digestive system, on “L-cells” that produce gut hormones, including GLP-1. When Amarasate triggers the bitter taste receptors on the part of the L-cell that faces into your intestines, those same cells release GLP-1 and other "stop eating” hormones from their other end.

There's actually some cool evolutionary logic here: our hunter-gatherer ancestors learned that bitter plants were often toxic, so developing a response that made them stop eating bitter foods helped them survive!

Research

You may think that because it’s a supplement, Calocurb’s going to rely on research that looked at the effects of its ingredients on animals or in the lab, with no human clinical studies. (Let’s face it, many supplements that are promoted for all sorts of things often refer to animal or lab studies as evidence that they’ll work in humans.) However, with Amarasate you can rely on proven science with the actual finished product (Calocurb) from human clinical research.

For example, when participants in a clinical study took Calocurb an hour before a meal, it caused the natural spike in GLP-1 to double, and the subjects subsequently ate almost 20% fewer calories!¹ That’s because this surge in your own GLP-1 helps you feel satisfied more quickly, which naturally dials down your appetite and how much you eat.

Additional research involving both male and female participants has demonstrated that Calocurb effectively reduces hunger and cravings during 24-hour fasting periods. The clinical data from those studies was impressive: in men, Calocurb reduced hunger by 20% but in women it was even more dramatic.² Calocurb slashed hunger by 30% and food cravings by 40% in the women’s study.³ What’s more, when the women got to eat at the end of the 24-hour fast, they ate almost 15% fewer calories (even though it had been 4 hours since their last Calocurb)!³ What’s more, a 6-month weight loss study to compare results in a group taking Calocurb with another group getting a placebo has just been completed in New Zealand. Expect those results to be revealed soon!

How to use it

For most use scenarios that basically aim to help reduce portion size, the recommended approach is to take Calocurb an hour before a meal, with a large glass of water. Begin with just one capsule daily, then gradually work up to two capsules before two different meals if you need to. Here's where individual differences come in: some people have bitter taste receptors that are particularly responsive to Amarasate (creating an even larger GLP-1 surge), while others have bodies that are especially sensitive to GLP-1's effects. These folks might need fewer capsules to see results. On the flip side, some people need to take more Calocurb to reach that sweet spot where they feel full enough to cut back on eating and achieve weight loss.

Side effects

The side effect profile for Calocurb is minimal: around 10% of people get a flushing (laxative) effect when first starting, but this typically resolves on its own and can be minimized by easing into it gradually rather than starting with a full dose right away. Nausea is uncommon with Calocurb and can be avoided by drinking a large glass of water when you take it.

Remember: Calocurb is classified as a supplement, so you don’t need a prescription to get it. A new version, Calocurb CLINICAL contains twice as much Amarasate as standard Calocurb. It’s only available through a practitioner, so talk to your doctor, dietitian, nutritionist, etc to find out about getting it.

The Injectable Route: GLP-1 Receptor Agonists Explained

What they do

Semaglutide and tirzepatide fall into a category called GLP-1 receptor agonists, but most people (including health practitioners) just call them “GLP-1s”. In plain English? They're copycats of your natural GLP-1. These are just two examples in a larger family—some versions are engineered to resist that DPP-4 enzyme that normally breaks down GLP-1 so that their effect is really prolonged, while others are derived from animals and closely resemble the human version. Regardless of their origin, they function as similar enough 'keys' to unlock those GLP-1 receptor 'locks' and flip them on.

How they’re taken

Most are delivered via injection under the skin given once a week for semaglutide and tirzepatide, though the FDA has just approved a daily oral form of Wegovy (semaglutide) for weight loss. Once injected (or swallowed), they saturate your system with GLP-1-like activity at levels far higher, steadier, and longer-lasting than what your body naturally experiences.

Side effects

GLP-1 receptor agonists are prescribed both for diabetes management through blood sugar reduction and for weight loss. That said, they frequently trigger digestive issues like indigestion, nausea, vomiting, and diarrhea, and more serious gastrointestinal problems have been documented as well. Additional side effects can include dizziness, headaches, and a slight uptick in heart rate. About 10% of people participating in clinical studies discontinued use because of side effects.

The sustained, extremely high levels of GLP-1 agonists flooding the system after injection likely account for both the therapeutic benefits and the unwanted effects—for instance, overstimulation of the brain region that triggers nausea. Because these medications break down slowly in the body, any side effects tend to stick around for a while. Calocurb, by comparison, works in harmony with your body's natural GLP-1 rhythm, but at double the typical levels you'd see after eating. This more natural pattern probably explains why nausea is far less common with Calocurb than with other GLP-1 medications.

Similarities and Differences

Both Calocurb and GLP-1 receptor agonists help you shed pounds through the same basic mechanism: relying on activation of GLP-1 receptors to slow down stomach emptying and boost feelings of fullness, which leads to eating less. Drugs like semaglutide or tirzepatide can be considered external 'simulators' or 'mimics' of the GLP-1 hormone, whereas the Amarasate in Calocurb is a 'stimulant' of our own internal GLP-1.

A major distinction with Calocurb is that it’s a very versatile, and natural, product. Its effect is to increase your own GLP-1 and enjoy the benefits by feeling full faster and so eating less for the 4-hour window that it’s active after you take it. That means, for example, if you’re attending a special dinner and want to enjoy it to the fullest, you can miss your usual dose of Calocurb beforehand and then start it again the next day. Or if you’ve noticed that you’re a premenstrual muncher, you may only want to take Calocurb in the week before your period is due. Maybe you’re doing intermittent fasting and doing the 5:2 diet; you might only need Calocurb on the two days a week that you’re eating very few calories.

Another benefit of Calocurb is that you can use it while you’re taking a GLP-1 receptor agonist. Some doctors recommend this so the dose of the prescription medication can be reduced without losing effectiveness. It also helps remind your body to continue production of natural GLP-1, which is very much suppressed when taking the injections.⁴ Finally, Calocurb provides an excellent “off ramp" for stopping the injections, by kickstarting your body’s production of natural GLP-1 and providing you with physiological and psychological support to help maintain your weight loss.

TLDR

Medications like Wegovy and Zepbound, and the supplement Calocurb, all work to increase your body’s activation of GLP-1 receptors. The prescription medications do so by simulating GLP-1 and putting your body’s GLP-1 receptors into constant prolonged activation. In contrast, Calocurb causes your body to make more of its natural GLP-1 through activation of bitter taste receptors throughout your gut, causing you to feel full faster for around four hours.

References

1. Walker EG, Lo KR, Pahl MC, et al. An extract of hops (Humulus lupulus L.) modulates gut peptide hormone secretion and reduces energy intake in healthy-weight men: a randomized, crossover clinical trial. Am J Clin Nutr. 2022;115(3):925-940. doi:10.1093/ajcn/nqab418
2. Walker E, Lo K, Tham S, et al. New Zealand bitter hops extract reduces hunger during a 24 h water only fast. Nutrients. 2019;11(11):2754. doi:https://doi.org/10.3390/nu11112754
3. Walker E, Lo K, Gopal P. Gastrointestinal delivery of bitter hop extract reduces appetite and food cravings in healthy adult women undergoing acute fasting. Obes Pillars. 2024;11:100117. Published 2024 Jun 20. doi:10.1016/j.obpill.2024.100117
4. Kim SH, Abbasi F, Nachmanoff C, et al. Effect of the glucagon-like peptide-1 analogue liraglutide versus placebo treatment on circulating proglucagon-derived peptides that mediate improvements in body weight, insulin secretion and action: a randomized controlled trial. Diabetes Obes Metab. 2021;23(2):489-498. doi:10.1111/dom.14242